---
title: Annex I — General Safety and Performance Requirements (GSPR)
description: EU MDR 2017/745 Annex I sets out the General Safety and Performance Requirements (GSPR) that medical devices must meet as the core basis for CE marking compliance.
regulation: EU MDR 2017/745
annex: Annex I
---

# Annex I — General Safety and Performance Requirements (GSPR)

**Source**: [EU MDR 2017/745 Annex I](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745) | OJ L 117, 5.5.2017

## Part I — General Requirements (GSPR 1–9)

| GSPR | Requirement Summary |
|------|---------------------|
| **GSPR 1** | Devices shall achieve their intended purpose and not compromise the clinical condition or safety of patients |
| **GSPR 2** | Risks shall be reduced as far as possible (AFAP); benefits shall outweigh residual risks |
| **GSPR 3** | Manufacturers shall establish, implement, document and maintain a risk management system (see [EN ISO 14971](../standards/risk-management)) |
| **GSPR 4** | Devices shall perform as intended under normal conditions of use |
| **GSPR 5** | Devices shall be designed and manufactured in accordance with the state of the art |
| **GSPR 6** | Benefits shall outweigh risks (benefit-risk analysis) |
| **GSPR 7** | Known and foreseeable risks shall be reduced as far as possible |
| **GSPR 8** | Devices shall perform in accordance with the manufacturer's intended purpose |
| **GSPR 9** | For devices with a diagnostic or measuring function, accuracy shall be ensured |

## Part II — Requirements for Design and Manufacture (GSPR 10–22)

| GSPR | Requirement Summary | Key Harmonised Standards |
|------|---------------------|--------------------------|
| **GSPR 10** | Chemical, physical and biological properties | [EN ISO 10993 series](../standards/biocompatibility) |
| **GSPR 11** | Infection and microbial contamination | [EN ISO 11135, 11607 series](../standards/sterilization) |
| **GSPR 12** | Devices containing substances or materials | EN ISO 10993-1 |
| **GSPR 13** | Interaction with the environment and other devices | — |
| **GSPR 14** | Electrical safety and electromagnetic compatibility | [EN IEC 60601 series](../standards/electrical-safety) |
| **GSPR 15** | Protection against mechanical risks | — |
| **GSPR 16** | Protection against radiation risks | — |
| **GSPR 17** | Electronic programmable systems and software | [EN IEC 62304](../standards/software) |
| **GSPR 18** | Active devices and devices connected to them | EN IEC 60601-1 |
| **GSPR 19** | Specific requirements (implantable devices) | — |
| **GSPR 20** | Specific requirements (devices incorporating a medicinal substance) | — |
| **GSPR 21** | Specific requirements (devices incorporating materials of human or animal origin) | — |
| **GSPR 22** | Specific requirements (IVD devices) | — |

## Part III — Requirements for Information Supplied with the Device (GSPR 23)

**GSPR 23 — Label and Instructions for Use**

Manufacturers shall provide:
- Label: device identification, intended purpose, manufacturer information, UDI, etc.
- Instructions for Use (IFU): all information necessary for safe use

Key harmonised standards: [EN ISO 15223-1, EN ISO 20417](../standards/labelling)

## GSPR Applicability Analysis

In clinical evaluation and technical documentation, manufacturers shall:
1. List all applicable GSPR clauses
2. Describe the method used to demonstrate conformity with each GSPR (harmonised standard / common specification / other method)
3. Provide evidence of conformity

## Related Pages

- [Harmonised Standards — Biocompatibility](../standards/biocompatibility)
- [Harmonised Standards — Risk Management](../standards/risk-management)
- [Harmonised Standards — Electrical Safety](../standards/electrical-safety)
- [Harmonised Standards — Software](../standards/software)
- [Article 52 — Conformity Assessment Procedures](./art-52-conformity-assessment)

## Official Sources

- [EUR-Lex: EU MDR 2017/745 full text (including Annex I)](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745)
- [MDCG 2019-16: Guidance on GSPR applicability](https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2019_16_guidance_gspr_en_0.pdf)
